Alterity CEO discloses initial share and option holdings

Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company.

Rhea-AI Filing Summary

Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company. He reports direct ownership of 11,688,312 ordinary shares and indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees (Australia) Limited. He also holds several option grants over ordinary shares with exercise prices ranging from $0.0030 to $0.0280 and expirations between August 2026 and August 2030, indicating a sizable long-term equity position.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Stamler David Allen

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Listed option exp 26 Feb 2027	--	--	--
holding	Listed option exp 31 August 2026	--	--	--
holding	Unlisted option exp 21 March 2029	--	--	--
holding	Unlisted option exp 8 August 2030	--	--	--
holding	Ordinary shares	--	--	--
holding	American Depositary Shares (1:600 ordinary shares)	--	--	--

Holdings After Transaction: Listed option exp 26 Feb 2027 — 1,515,152 contracts (Direct); Listed option exp 31 August 2026 — 2,380,952 contracts (Direct); Unlisted option exp 21 March 2029 — 40,000,200 contracts (Direct); Unlisted option exp 8 August 2030 — 290,400,000 contracts (Direct); Ordinary shares — 11,688,312 shares (Direct); American Depositary Shares (1:600 ordinary shares) — 139,258 shares (Indirect, HSBC Custody Nominees (Australia) Limited)

Key Figures

Direct ordinary shares: 11,688,312 shares Indirect ADS holdings: 139,258 ADS Option exp 26 Feb 2027: 1,515,152 underlying shares at $0.0280 +3 more

6 metrics

Direct ordinary shares 11,688,312 shares Total ordinary shares directly held as of Form 3

Indirect ADS holdings 139,258 ADS American Depositary Shares held via HSBC Custody Nominees

Option exp 26 Feb 2027 1,515,152 underlying shares at $0.0280 Listed option over ordinary shares, direct ownership

Option exp 31 Aug 2026 2,380,952 underlying shares at $0.0100 Listed option over ordinary shares, direct ownership

Option exp 21 Mar 2029 40,000,200 underlying shares at $0.0030 Unlisted option over ordinary shares, direct ownership

Option exp 8 Aug 2030 290,400,000 underlying shares at $0.0086 Unlisted option over ordinary shares, direct ownership

Key Terms

Form 3, American Depositary Shares (1:600 ordinary shares), Listed option, Unlisted option, +1 more

5 terms

Form 3 regulatory

"Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

American Depositary Shares (1:600 ordinary shares) financial

"American Depositary Shares (1:600 ordinary shares) with indirect ownership reported"

Listed option financial

"Listed option exp 26 Feb 2027 over Alterity ordinary shares"

Unlisted option financial

"Unlisted option exp 8 August 2030 with underlying ordinary shares"

indirect ownership financial

"indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Alterity Therapeutics (ATHE) Form 3 filing show for CEO David Stamler?

The Form 3 shows that CEO David Stamler reported his initial beneficial ownership in Alterity Therapeutics. He holds ordinary shares directly, additional American Depositary Shares indirectly, and several option grants over ordinary shares with various exercise prices and expirations, indicating significant equity exposure.

How many Alterity Therapeutics ordinary shares does the CEO directly hold?

The CEO reports direct ownership of 11,688,312 ordinary shares of Alterity Therapeutics. This figure reflects his direct equity stake as of the Form 3 date and is separate from any options or indirect American Depositary Share holdings disclosed in the same filing.

What options over Alterity Therapeutics shares are disclosed in the Form 3?

The filing lists multiple options over Alterity ordinary shares with different terms. These include listed and unlisted options with exercise prices from $0.0030 to $0.0280 and expiration dates between August 2026 and August 2030, each tied to specific underlying share amounts.

What indirect holdings in Alterity Therapeutics does the CEO report?

The CEO reports indirect ownership of 139,258 American Depositary Shares in Alterity Therapeutics. These are held through HSBC Custody Nominees (Australia) Limited, as noted in the filing, and are reported separately from his directly held ordinary share position and option grants.

Does the Alterity Therapeutics Form 3 show any insider buying or selling activity?

The Form 3 functions as an initial ownership report and shows holdings rather than trades. The filing classifies all entries as holdings with unknown transaction codes, so it does not indicate new insider buying or selling activity, only existing positions as of the reporting date.

What are the key expiration dates for the CEO’s Alterity Therapeutics options?

The disclosed options expire on several dates: August 31, 2026; February 26, 2027; March 21, 2029; and August 8, 2030. Each expiration date corresponds to a separate option grant over a defined number of Alterity ordinary shares at a specified exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 07:49 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stamler David Allen

(Last) (First) (Middle)

39899 BALENTINE DRIVE

(Street)

NEWARK CALIFORNIA 94560

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
ALTERITY THERAPEUTICS LTD [ ATHE ]

3a. Foreign Trading Symbol
[ATH.ASX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	11,688,312	D
American Depositary Shares (1:600 ordinary shares)	139,258	I	HSBC Custody Nominees (Australia) Limited

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Listed option exp 26 Feb 2027	04/15/2026	02/26/2027	Ordinary shares	1,515,152	$0.028	D
Listed option exp 31 August 2026	04/15/2026	08/31/2026	Ordinary shares	2,380,952	$0.01	D
Unlisted option exp 21 March 2029	04/15/2026	03/21/2029	Ordinary shares	40,000,200	$0.003	D
Unlisted option exp 8 August 2030	04/15/2026	08/08/2030	Ordinary shares	290,400,000	$0.0086	D

Explanation of Responses:

	David Allen Stamler	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)